Sign up & Download
Sign in

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.

by Tatsuya Katayama, Junichi Shimizu, Kenichi Suda, Ryoichi Onozato, Takayuki Fukui, Simon Ito, Shunzo Hatooka, Taijiro Sueda, Toyoaki Hida, Yasushi Yatabe, Tetsuya Mitsudomi show all authors
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer ()


The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the epidermal growth factor receptor (EGFR) gene was previously reported. We speculate that erlotinib, instead of high dose of gefitinib, may be also effective for the treatment of central nervous system (CNS) lesions, as trough serum concentration of erlotinib is nine times higher than that of gefitinib.

Cite this document (BETA)

Readership Statistics

24 Readers on Mendeley
by Discipline
by Academic Status
17% Researcher (at an Academic Institution)
17% Other Professional
13% Ph.D. Student
by Country
4% Japan

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in